// App-Quantinova.ai

: Dynamics of Response and Response Factors in Patients (Pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) after ≥2 Prior Tyrosine Kinase Inhibitors (TKIs) in the Phase 3 Ascembl Study

Researchers

Presenter

  • Timothy Hughes

Principal Investigators

  • Delphine Rea

  • Carla Boquimpani

  • Yosuke Minami

  • Michael Mauro

  • Jorge E. Cortes

  • Jane F. Apperley

  • Valentin Garcia Gutierrez

  • Shruti Kapoor

  • Alex Allepuz

  • Sarah Quenet

  • Yifan Zhang

  • Andreas Hochhaus

Medical Centers

  • Hopital Saint-Louis, Paris, France

  • HEMORIO, State Institute of Hematology Arthur de Siquiera Cavalcanti, Rio de Janeiro, Brazil

  • South Australian Health and Medical Research Institute SAHMRI, Adelaide, Australia

  • National Cancer Center Hospital East, Kashiwa, Japan

  • Georgia Cancer Center, Augusta, GA

  • Universitatsklinikum Jena, Jena, Germany

  • Hematology Service, Hospital Universitario Ramón y Cajal. IRYCIS, Madrid, Spain

  • Centre for Haematology, Department of Immunology and Inflammation, Imperial College London, London, United Kingdom

  • Novartis Pharma AG, Basel, SWITZERLAND

  • Memorial Sloan Kettering Cancer Center, New York, NY

Locations

  • France

  • United Kingdom

  • Germany

  • Japan

  • Brazil

  • Switzerland

  • Spain

  • United States

  • Australia

Companies

  • Novartis AG

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Chronic Myelogenous Leukemia

Biomarkers

  • Breakpoint Cluster Region

  • Cluster of Differentiation 206

Drug/Treatment

  • ABL001

  • L-Tyrosine

Outcome

  • N/A

Study Design

  • Randomized

  • Efficacy

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved